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mild MR at baseline were in NYHA class III or IV.
Conclusion: Moderate or severe MR in patients undergoing TAVR is associated with
a higher short-term, but not long-term, mortality. MR improves in approximately half
of the patients with moderate or severe MR post TAVR.
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Clinical Outcomes of Patients with PARTNER Trial Exclusions
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Background: The randomized PARTNER trial excluded patients with conditions
frequently encountered in clinical practice.
Methods: 242 consecutive high-risk patients (STS >10) undergoing trancatheter aortic
valve implantation (TAVI) were assessed. Patients were divided into a “PARTNER-
exclusions” (PE) group (ejection fraction <20%, severe mitral regurgitation, creatinine
>3.0 mg/dl and/or hemodialysis, significant coronary disease, recent coronary stenting,
cerebrovascular accident within 6-months, annulus diameter <16mm/>24mm, bicuspid
valve, aortic regurgitation >3+, prior valve surgery) and “no PARTNER exclusion”
(NPE) group. The last 4 criteria were also sub-analyzed as “technical exclusions”.
Results: 12-month KM-survival estimates for the PE group were 68.1% vs. 78.2% for
the NPE group (p=0.14). At 3-years this was 40.1% vs. 61.9%, p=0.04. The unadjusted
HR for 3-year mortality for the PE group was 1.61 (95% CL 1.01-2.56), but when
adjusted for baseline differences using a proportional hazard model this was no longer
significant–HR 1.36 (95%CL 0.79-2.35). There were no significant differences in
adjusted survival between the technical groupings either within 30-days (p=0.60) or
1-year (p=0.07). Technical exclusions were not associated with procedural failures and
procedural success rates were excellent (>98%). Ejection fraction <20% trended
(p=0.053) towards lower unadjusted 12-month survival. Patients with severe mitral
regurgitation had similar 12-month survival compared to those without severe
regurgitation.
Conclusion: Patients undergoing TAVI who meet exclusion criteria for the PARTNER
trial represent a high-risk cohort with higher unadjusted long-term mortality, but similar
long-term outcomes when adjusted for baseline risk. Patients with technical exclusion
criteria can still have highly successful procedures. This has important implications
for selection of patients with future “off –label” indications.
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PREDICTORS OF AVB AFTER TAVR WITH THE BOTH EDWARDS AND
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Background: To compare the predictors of high grade atrio-ventricular block (AVB)
after transcatheter aortic valve replacement (TAVR) with the Edwards-Sapien™ THV
(Edwards Lifesciences, Irvine, California) (ESV) and CoreValve ReValving System®
(CoreValve Medtronic Inc, Minneapolis, Minnesota, USA) (CVR)
Methods: We included all consecutive patients undergoing successful TAVR in our
center from November 2007 to March 2011; we excluded 25 patients who had already
a permanent pacemaker and 24 patients whom electrocardiography analysis were not
available.
Results: The study cohort comprised 228 patients: 85 CVR and 143 ESV. Fifty-percent
of the patients were male (63.5% in CVR vs. 46.2% in ESV; p=0.01) and the mean
age was 79±7 years. The patients who underwent TAVR with CVR had a higher
prevalence of poor LVEF (20.0% vs. 10.5%; p=0.04). Baseline electrocardiography
showed a higher prevalence of left bundle brunch block (LBBB) in the CRV then ESV
group (21.2% vs. 8.4%; p=0.006), similar prevalence of right bundle brunch block
(RBBB) (16.5% vs. 13.3%; p=0.50) and wider QRS complex in the CRV then ESV
group (112.6±27.1 ms vs. 105.7±23.4 ms; p=0.04). The incidence of high degree AVB
was higher after CVR (n=15) then ESV (n=10) implantation (17.6% vs. 7.0%; p=0.01).
The multivariable predictors of AVB after TAVR were CVR vs. ESV implantation (OR
2.43, 95%CI 1.00-5.91; p=0.05) and wider baseline QRS (OR 1.02, 95%CI 1.01-1.04;
p<0.001). The univariate predictors of AVB after CVR implantation were the RBBB
(OR 7.87, 95%CI 2.18-28.32; p=0.002) and the wider QRS complex (OR 1.04, 95%CI
1.01-1.06; p<0.001), meanwhile poor LVEF (OR 7.39, 95%CI 1.81-30.21; p=0.005)
and the depth of prosthesis implantation (OR 1.45, 95%CI 1.0-2.06; p=0.03) were the
univariate predictors of AVB after ESV implantation.
Conclusion: The main predictors of AVB after TAVI seem to be the CVR vs. ESV
implantation and a wider QRS complex. RBBB and the wider QRS complex seem to
be predictors in case of CVR implantation, whereas poor LVEF and the depth of
prosthesis implantation seem to be predictors of AVB in the case of ESV implantation.
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Gender differences in patients undergoing transcatheter aortic valve
implantation with the Medtronic CoreValve System
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Background: Gender differences in patients undergoing surgical aortic valve
replacement are well documented. Whether gender differences exist in patients
undergoing TAVI is unknown.
Methods: From June 2007 to June 2010, we enrolled 333 consecutive patients who
underwent Medtronic CoreValve implantation. Baseline characteristics and clinical
outcomes were prospectively entered into a dedicated database and differences between
genders were investigated. The primary end-point consisted of a composite outcome
of 1-year mortality.Differences in survival outcomes between genders were estimated
by Kaplan-Meier survival curves.
Results: 152 (46%) were male and 181 (54%) were female. Males had a larger left
ventricular end-diastolic dimensions (51.5 ± 7.7 vs. 45.07 ± 7 mm, p<0.001) and aortic
annulus size (25 ± 1.04 vs. 22.6 ± 1.5 mm, p<0.001) than females. Females were
characterized by higher transaortic mean gradient(49.7 ± 17.7 vs. 45 ± 16 mmHg, p=
0.013). Males were more likely to have coronary artery disease (61.2 vs. 44.7%, p=
0.003) and previous history of coronary artery bypass surgery (28 vs. 6.6%, p<0.001),
more peripheral arterial disease (28 vs. 10.5%, p<0.001), higher baseline creatinine
levels (1.36 ± 0.5 vs. 1.07 ± 0.47 mg/dl, p=<0.001), lower ejections fraction <35%
(23.4 vs. 8.4%, p<0.001), and higher logistic EuroSCORES (21.4 ± 14.4 vs. 17.4 ±
10.7%, p= 0.007). A 26-mm CoreValve was implanted in 62% of females and a 29-
mm CoreValve in 79% in males. Kaplan-Meier survival analyses did not demonstrate
any differences between genders with regards to 30-day or 1-year mortality. Males
were more likely to require post-implant dilatation (28.6 vs. 16.9%, p= 0.011) for
significant paravalvular aortic regurgitation whereas females had a higher occurrence
of post-procedural pericardial effusion > 1cm (4.4 vs. 0%, p= 0.009).
Conclusion: In the current study, males undergoing TAVI had more comorbidities and
higher logistic EuroSCORES than females. There were no significant differences in
30-day or 1-year mortality between genders.
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Background: Prosthesis embolization during transcatheter aortic valve implantation
(TAVI) is a rare but important complication, and data on prosthesis performance placed
far from its anatomic position are sparse. We sought to investigate the causes of self-
expanding CoreValve embolization during TAVI and mid-term follow-up of patients
experiencing this acute complication.
Methods: Among 176 consecutive patients undergoing TAVI with CoreValve
prosthesis, 7 (3.9%) experienced acute valve embolization. Accurate analysis of
mechanism of embolization, clinical outcomes and performance of embolized
prosthesis were investigated.
Results: The reasons of valve embolization were classified into three groups: 1)
accidental embolization immediately after valve implantation (N=1; 14.3%) 2)
Embolization during snaring maneuver to reposition a low deployment of the CRS
prosthesis (lower edge >10 mm) below the aortic annulus accompanied with
hemodynamically significant regurgitation (N=4; 57.1%); 3) intentional embolization
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performed with snaring maneuver as a bailout in cases of coronary ostia impairment
or severe prosthetic leak due to higher deployment for a suboptimal sealing of the
device with valve calcifications (N=2; 28.6%). The majority of accidental embolization
occurred during early experience with the new Accutrak delivery system. In 6 a second
CRS in the correct position was implanted. The misplaced CRS functioned normally,
with no instances of structural deterioration, thrombosis or further distal migration,
and showed complete apposition against the aortic wall. Moreover, no thromboembolic
events were reported in any patient.
Conclusion: CRS embolization can be effectively managed, implanting a second
prosthesis in a standard fashion and leaving the misplaced device in aorta. There seem
to be no long term vascular or neurological adverse events associated with device
embolization or intentional relocation in experienced hands.
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Requirement of Small Size of Prosthetic Aortic Valve in Asian Population;
Implication to Select Valve Size for Transcatheter Aortic Valve Implantation in
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Background: Currently an efficacy of transcatheter aortic valve implantation (TAVI)
has been proved as a less invasive treatment for high risk elderly patients with aortic
stenosis in Europe and United States, and many patients received TAVI. However, there
is no data regarding to appropriate size of aortic valve by TAVI in Asian population
who has smaller build than those in Europe and United states. To clarify aortic annular
size in Japanese patients with aortic stenosis, the following study was evaluated.
Methods: Between May 2004 and December 2008, consecutive 340 patients (male:
158, female: 182) who underwent surgical replacement of aortic valve for aortic
stenosis were studied. Study subjects included tricuspid anatomy in 224 patients and
bicuspid in 116 patients. Because of indication for TAVI, patients with tricuspid
anatomy were evaluated by TTE (transthoracic echocardiography) and TEE
(transesophageal echocardiography). We analyzed the sizes of annulus and implanted
valve.
Results: Patient age was 72.9±8.4 years old (male) and 75.8±6.8 years old (female).
Annulus diameter was 21.1±2.1 mm (male 22.3±1.9 mm, female 20.3±1.9 mm,
p<0.001). The average annulus diameter above 75 years old also had larger size in
male than female (n=42, 22.3±2.0 mm vs n=82, 20.1±1.8 mm). Implanted valve was
smaller than measured annulus both in male (21.7±1.4 mm) and female (19.3±1.3 mm).
Small size valve bellow 20 mm was counted in 31.5% of whole patients, and 46.3%
of female elderly above 75 years old.
Conclusion: Asian population including Japanese shall need a smaller size of
prosthetic aortic valve in elderly. Furthermore, considering the thickness of sewing
ring of tissue valve, Euro-American population may also require a small size valve in
case of value-in-valve technique.
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Background: Transcatheter aortic valve implantation is a therapeutic alternative for
high-surgical-risk patients with severe symptomatic aortic stenosis. Two models of
prosthesis are currently commercialized in France, which can be implanted either via
a transarterial or a transapical approach. The aim of the study was to evaluate in a
national French registry the early safety and efficacy of transcatheter aortic valve
replacement (AVR) using either the Edwards valves or CoreValve in high-surgical-risk
patients with severe aortic stenosis.
Methods: The multicentre national registry was conducted in 33 centres between
January 2010 and July 2011, under the authority of the French Societies of Cardiology
and Thoracic and Cardio-Vascular Surgery. All the valves implanted in France since
the study period were included. The primary endpoint was mortality at 1 month,
6month, 1 year up to 5 year.
Results: Two thousand and five hundred high-surgical-risk patients (logistic
EuroSCORE ≥20%, STS ≥10%, or contra-indication to AVR) were enrolled. Mean age
was 82+7 years and 43.9% were female. Edwards valves and CoreValve were
implanted in 68 and 32% of patients, respectively. The approaches used were
transarterial (transfemoral: 66%; subclavian: 5%) or transapical in 29%. Device success
rate was xx and mortality was xx, xx, xx respectively at 30 days, 6 month and 12
month. Severe complications included stroke (xx), tamponade (xx), acute coronary
occlusion (xx), and vascular complications (xx). Pacemaker was required in xx. At 1
month, xx of patients were in NYHA class II or less, xx at 6 month and xx at 1 year.
All the result will be receive at the end of August 2011
Conclusion: This prospective registry reflects the real-life experience of transcatheter
aortic valve implantation in high-risk elderly patients in France. This registry is the
first exhaustive and consecutive registry included the 2 types of percutaneous aortic
valves
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Background: The percentage of patients eligible for first-generation balloon-
expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, California, USA)
implantation was restricted to definite aortic annulus diameters. Moreover, transfemoral
implantation using this device was limited to patients with large bore iliac-femoral
arteries. This study sought to assess the proportion of patients anatomically suitable
for the current Edwards SAPIEN XT (ES-XT) valve using NovaFlex/E-Sheath delivery
system compared with the past Edwards SAPIEN (ES) valve with RetroFlex 3 delivery
system, including both transfemoral and transapical approaches.
Methods: All high surgical risk patients with severe aortic stenosis referred to our
department as potential candidates for TAVI, underwent transesophageal
echocardiography and angiography of aorta and iliac-femoral arteries in order to assess
anatomical suitability by different approaches. The transfemoral access requirements
for ES/RetroFlex 3 system were a minimal iliofemoral lumen diameter of at least 7
mm for the 22-F/23-mm device and a minimal iliofemoral dimension of at least 8 mm
for the 24-F/26-mm device. The current ES-XT with NovaFlex/E-Sheath delivery
system requires a minimal iliofemoral dimension of at least 6 mm for the 23 mm valve
(NovaFlex 18F/E-Sheath 16F) and 6.5 mm for the 26 mm valve (NovaFlex 19F/ E-
Sheath 18F). The range of annulus diameter considered amenable for implantation was
18-25 mm for the ES valve (23 and 26 mm prosthesis) and 18-27.5 mm for ES-XT
valve (23, 26 and 29 mm prosthesis). Transfemoral approach was considered as the
first option, if not suitable the patient was evaluated for transapical approach.
Results: Data were collected for 293 high-risk patients evaluated for TAVI. Anatomic
suitability was 82% (240/293) for ES RetroFlex versus 95% (277/293) for ES-XT
NovaFlex/E-Sheath. Among 240 patients eligible for ES RetroFlex, 80 (33%) were
suitable for transfemoral implantation, while among 277 patients eligible for ES-XT,
those suitable for tranfemoral approach were 172 (62%).
Conclusion: Using current Edwards devices the percentage of patients suitable for
TAVI increases from 82% to 95%. Moreover, while only 1/3 of patients had anatomic
criteria suitable for the less-invasive transfemoral approach with the previous devices,
with the current Edwards SAPIEN devices this proportion increases to about 2/3 of
patients.
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Background: Although impaired LV function may be considered a contra-indication
for aortic valve replacement, the hemodynamic characteristics of transcatheter valves
may offer procedural and long-term clinical benefit in such patients. We sought to
determine the prevalence of impaired LV systolic function and its impact on the in-
hospital and long-term outcome in patients who underwent Transcatheter Aortic Valve
Implantation (TAVI).
Methods: 230 consecutive patients underwent TAVI with the Medtronic-CoreValve
System. Impaired LV function was defined by LVEF ≤35% (European Multicenter
Study on Operative Risk Stratification and Long-term Outcome in patients with Low-
Flow/Low-Gradient Aortic Stenosis). Study endpoints were defined according to the
Valve Academic Research Consortium recommendations.
Results: Compared to patients with a LVEF >35% (n=197), those with LVEF ≤35%
(n=33) were more often male (78.8 % vs. 46.7%, p<0.001), more symptomatic (NYHA
class III / IV, 97.0% vs. 77.2%, p=0.008) and had a higher prevalence of prior coronary
artery disease (63.6% vs. 43.1%, p=0.029). The Logistic EuroSCORE was 14.8% and
22.8%, respectively (p=0.012). No difference was observed between the 2 groups in
in-hospital or 30-day mortality (3.0% vs. 9.6%, p=0.21), the Combined Safety Endpoint
at 30 days (24.2% and 24.4% p=0.99) and survival free from readmission at 2 years
(61.5% and 59.3%). After adjustment, LVEF ≤ 35% was not associated with an
increased risk of 30-day mortality, in-hospital complications and survival free from
readmission at follow-up.
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